XM does not provide services to residents of the United States of America.

Cognizant sues software rival Infosys over trade secrets



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 1-Cognizant sues software rival Infosys over trade secrets</title></head><body>

Adds Infosys response in paragraph 3

By Blake Brittain

Aug 23 (Reuters) -Software provider Cognizant TriZetto AXPAST.UL sued Indian tech company Infosys INFY.NS in Texas federal court on Friday, accusing Infosys of stealing trade secrets related to its healthcare insurance software.

Cognizant said in the lawsuit that Infosys unlawfully extracted data from its databases and used it to build and market competing software.

Infosys denied the allegations in a statement and said it would defend itself in court. Spokespeoplefor Cognizant did not immediately respond to a request for comment on the complaint.

Teaneck, New Jersey-based Cognizant's software includes TriZetto's Facets and QNXT, used by healthcare insurance companies to automate administrative tasks.

According to the complaint, Infosys misused TriZetto's software to create "Test Cases for Facets," which improperly repackaged TriZetto's data into an Infosys product.

Cognizant also said Infosys broke the law by creating software to extract data from QNXT that includes confidential TriZetto information and trade secrets.

Cognizant earned more than $19.3 billion in revenue last year while Infosys earned more than $18.5 billion, according to company reports.

Cognizant asked the court for an unspecified amount of monetary damages and an order for Infosys to stop misusing its trade secrets.

Cognizant won $854 million from Atos' ATOS.PA Syntel in a separate dispute over Facets trade secrets in 2020. The award was later cut and then overturned on appeal last year, though the court found that Syntel was still liable for an amount of damages to be determined.


The case is Cognizant TriZetto Software Group Inc v. Infosys Ltd, U.S. District Court for the Northern District of Texas, No. 3:24-cv-02158.

For Cognizant: Kieran Kieckhefer, Betty Yang, Ahmed ElDessouki and Elizabeth McCloskey of Gibson Dunn & Crutcher

For Infosys: Attorney information not yet available


Read more:

Cognizant's $570 million trade-secret case win against Syntel thrown out on appeal


</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.